Comparative Pharmacology
Head-to-head clinical analysis: ACTICLATE versus VIBRAMYCIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ACTICLATE versus VIBRAMYCIN.
ACTICLATE vs VIBRAMYCIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibits P-glycoprotein (P-gp) and breast cancer resistance protein (BCRP), thereby increasing intestinal absorption and decreasing clearance of substrates; also inhibits CYP3A4 isoenzymes, reducing metabolism of CYP3A4 substrates.
Inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, preventing addition of amino acids to the growing peptide chain. Bacteriostatic.
100 mg orally twice daily (12 hours apart) on an empty stomach (1 hour before or 2 hours after meals). Avoid milk, antacids, iron, calcium, magnesium, and zinc within 2 hours of administration.
100 mg orally or intravenously every 12 hours on day 1, then 100 mg once daily; severe infections: 100 mg every 12 hours.
None Documented
None Documented
Terminal elimination half-life is approximately 18-22 hours in patients with normal renal function; prolonged to 30-50 hours in moderate renal impairment (CrCl 30-50 mL/min).
Terminal elimination half-life is 16-18 hours in patients with normal renal function. Prolonged to 20-36 hours in severe renal impairment; no significant change in hepatic impairment.
Renal excretion of unchanged drug accounts for approximately 60% of the dose; fecal elimination via biliary secretion contributes about 30%; minor metabolism (<10%) produces inactive metabolites.
Approximately 40% excreted unchanged in urine via glomerular filtration; 20-25% eliminated in feces via biliary secretion; remainder metabolized. Renal clearance is about 30 mL/min.
Category C
Category C
Tetracycline Antibiotic
Tetracycline Antibiotic